Response to: ‘Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina <i>et al</i>

Duret, Pierre-Marie; Spielmann, Lionel; Messer, Laurent

doi:10.1136/annrheumdis-2020-218147

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are similar to those reported by Duret et al [8] and the use of DMARDs does not seem to contribute to an unfavorable evolution of COVID-19. Rheumatologists however should pay special attention to the use of rituximab as, due to its distinct mechanism of action, may be associated to complications and a worse outcome in SARS-CoV-2 infection.…”

supporting

confidence: 92%

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy

et al. 2020

View full text Add to dashboard Cite

supporting

confidence: 92%

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy

et al. 2020

View full text Add to dashboard Cite

“…Our systematic search of the literature allowed us to identify 37 case reports and case series 20‐56 and 11 studies that corresponded to our research question but their data were provided descriptively and an effect measure could not be calculated 21,57‐66 . These data are included in Table S1.…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments

Kokkotis

Kitsou

Xynogalas

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Accumulating evidence suggests a beneficial effective of tumour necrosis factor‐alpha (TNF‐α) inhibitors on the outcomes of COVID‐19 disease, which, however is not validated by all studies. Aims To perform a systematic review and meta‐analysis of existing reports to investigate the impact of anti‐TNF treatments on the clinical outcomes of COVID‐19 patients. Methods A systematic search at PubMed and SCOPUS databases using specific keywords was performed. All reports of COVID‐19 outcomes for patients receiving anti‐TNF therapy by September 2021 were included. Pooled effect measures were calculated using a random‐effects model. The Newcastle Ottawa Scale for observational studies was used to assess bias. Studies that were not eligible for meta‐analysis were described qualitatively. Results In total, 84 studies were included in the systematic review, and 35 were included in the meta‐analysis. Patients receiving anti‐TNF treatment, compared to non‐anti‐TNF, among COVID‐19 cases had a lower probability of hospitalisation (eight studies, 2555 patients, pooled OR = 0.53, 95% CI: 0.42‐0.67, I2 = 0) and severe disease defined as intensive care unit admission or death (two studies, 1823 patients, pooled OR = 0.63, 95% CI: 0.41‐0.96, I2 = 0), after adjustment for validated predictors of adverse disease outcomes. No difference was found for the risk for hospitalisation due to COVID‐19 in populations without COVID‐19 for patients receiving anti‐TNF treatment compared to non‐anti‐TNF (three studies, 5 994 958 participants, pooled risk ratio = 0.97, 95% CI: 0.68‐1.39, I2 = 20) adjusted for age, sex and comorbidities. Conclusions TNF‐α inhibitors are associated with a lower probability of hospitalisation and severe COVID‐19 when compared to any other treatment for an underlying inflammatory disease.

show abstract

“…Some case reports emphasized that patients on TNF-α blockers due to rheumatological diseases were infected by Covid-19 during their treatment; nevertheless, there was no deterioration in disease prognosis. In fact, it was suggested that the use of other anti-inflammatory drugs for Covid-19 was beneficial in disease prognosis (17).Accordingly, TNF-α blockers may be considered in Covid-19 patients with DM, who develop excessive inflammation. Efficacy of steroids as a treatment option for Covid-19 infections has been suggested in cases of hypoxemia (18).…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Hastalarında TNF-α Düşüşünü Etkileyen Faktörler

GÜLHAN,

ALPAY,

YILDIZ

et al. 2024

Sağlık Bilimlerinde Değer

View full text Add to dashboard Cite

Aim: Tumor necrosis factor-alpha (TNF-α) have several functions, including cell survival, differentiation, and proliferation. TNF-α may effect the cell death during the cytokine storm that occurred during COVID-19 infection. We aimed to investigate, the factors that affects the TNF-α decrease in COVID-19 patients. Material and Methods: Totally 44 individuals with COVID-19 infection were included the study. Blood counts, biochemical examinations and D-dimer examinations were obtained. Comorbidities and initial symptoms of the patients were recorded. TNF-α, CRP and ferritin values were measured twice on the 1st and 7th days of hospitalization. The change in this values were examined according to comorbidities, initial symptoms and steroid usage. Results: Of a total of 44 patients, 56.8% were male (25/44) and 43.2 % were female (19/44). TNF-α decrease was found to be statistically significant in non-diabetic patients, while TNF-α decrease was found to be insignificant in diabetic patients. CRP decrease was found to be statistically significant in both diabetic and non-diabetic patients while ferritin decrease was insignificant in both diabetic and non-diabetic patients. While TNF-α and CRP decreased statistically significantly in those without lung disease, it was observed that both TNF-α and CRP decreases were not significant in those with lung disease. The decrease in TNF-α and CRP was statistically insignificant in those who did not treated with steroids, while the decrease in TNF-α and CRP was significant in those who treated with steroids. Conclusion: Steroids decreases the TNF-α levels. TNF decrease is not significant in those with diabetes and lung disease.

show abstract

Response to: ‘Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina et al

Cited by 7 publications

References 21 publications

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy

Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments

COVID-19 Hastalarında TNF-α Düşüşünü Etkileyen Faktörler

Contact Info

Product

Resources

About